AR040484A1 - Un compuesto, un proceso para la preparacion de dicho compuesto, y una composicion farmaceutica que comprende dicho compuesto - Google Patents
Un compuesto, un proceso para la preparacion de dicho compuesto, y una composicion farmaceutica que comprende dicho compuestoInfo
- Publication number
- AR040484A1 AR040484A1 AR20030102488A ARP030102488A AR040484A1 AR 040484 A1 AR040484 A1 AR 040484A1 AR 20030102488 A AR20030102488 A AR 20030102488A AR P030102488 A ARP030102488 A AR P030102488A AR 040484 A1 AR040484 A1 AR 040484A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- compound
- represented
- macrolide
- reacting
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 20
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000003120 macrolide antibiotic agent Substances 0.000 abstract 8
- 150000003431 steroids Chemical class 0.000 abstract 4
- 125000003277 amino group Chemical group 0.000 abstract 3
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 3
- 230000028993 immune response Effects 0.000 abstract 2
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 abstract 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- -1 ICAM Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 108010002352 Interleukin-1 Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 102100040247 Tumor necrosis factor Human genes 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 abstract 1
- 239000003862 glucocorticoid Substances 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Un proceso para la preparación de dicho compuesto y una composición farmacéutica que comprende dicho compuesto. Los compuestos están representados por la fórmula (1): tales compuestos inhiben muchas citoquinas y mediadores inmunes involucrados en la respuesta inmune que provoca inflamación, alergia o aloinmunidad, que incluyen sin alimentación a IL-1, 2, 4, 5, 6, 10, 12, GMCSF, ICAM, y TNF-a. Es importante senalar que los esteroides anti-inflamatorios ejercen un efecto directo anti-inflamatorio a través de unirse al receptor glucocorticosteroide. Reivindicación 1: Un compuesto de la fórmula (1) caracterizado porque: i) M es una subunidad macrólido seleccionada del grupo que consiste de moléculas de anillos lactónicos de multimiembros, en donde "miembro" se refiere a la cantidad de átomos de carbono o heteroátomos en el anillo lactónico y "multi" significa una cantidad total mayor de alrededor de 10, hasta alrededor de 18 de dichas moléculas que tienen la propiedad de acumularse dentro de las células del sistema inmune que median la respuesta inmune inflamatoria de los mamíferos, incluyendo los seres humanos; ii) S es una subunidad anti-inflamatoria esteroidea; iii) L es una molécula conectora a la cual cada una de M y S está covalentemente unidas. Reivindicación 48: Un proceso para la preparación de un compuesto de la fórmula (1) de la reivindicación 1, caracterizado porque comprende: a) para un compuesto representado por la fórmula (1), donde X2 es -NHC(O)-, haciendo reaccionar un compuesto de la fórmula (2): en donde L1 representa un grupo de partida y un grupo amino libre de un macrólido representado por la fórmula (3); b) para un compuesto representado por la fórmula (1), en donde X2 es -OC(O)-, haciendo reaccionar un compuesto de la fórmula (2) y un grupo hidroxilo de un macrólido representado por la fórmula (4); c) para un compuesto representado por la fórmula (1), en donde X1 es -OC(O)-, Q es NH y X2 es -NHC(O)-, haciendo reaccionar un macrólido representado por la fórmula (5) y un grupo amino libre representado por la fórmula (6); d) para un compuesto representado por la fórmula (1), en donde X1 es -OC(O)NH- y X2 es -NHC(O)-, haciendo reaccionar un macrólido representado por la fórmula (7) y un grupo amino libre de la fórmula (6); e) para un compuesto representado por la fórmula (1), en donde X1 es -CH2-, Q es -NH- y X2 es -NHC(O)-, haciendo reaccionar un macrólido representado por la fórmula (8) y un compuesto de la fórmula (2); f) para un compuesto de la fórmula (1), haciendo reaccionar un macrólido representado por un compuesto seleccionado del grupo de fórmulas (9) que tienen un grupo de partida L2, con ácido carboxílico libre del esteroide representado por la fórmula (10); g) para un compuesto representado por la fórmula (1), en donde X1 es -OC(O)-, Q es NH y X2 es -NH- haciendo reaccionar un macrólido representado por la fórmula (11), y una subunidad esteroide que tiene una unión -C=C- representado por la fórmula (12) seguido por la modificación del grupo RC.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39467002P | 2002-07-08 | 2002-07-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040484A1 true AR040484A1 (es) | 2005-04-06 |
Family
ID=30115752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AR20030102488A AR040484A1 (es) | 2002-07-08 | 2003-07-10 | Un compuesto, un proceso para la preparacion de dicho compuesto, y una composicion farmaceutica que comprende dicho compuesto |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7091187B2 (es) |
| EP (1) | EP1521764A2 (es) |
| JP (1) | JP4790263B2 (es) |
| CN (1) | CN100577681C (es) |
| AR (1) | AR040484A1 (es) |
| AU (1) | AU2003255851B2 (es) |
| BR (1) | BR0312634A (es) |
| CA (1) | CA2489402A1 (es) |
| IS (1) | IS7684A (es) |
| NO (1) | NO329885B1 (es) |
| NZ (1) | NZ537717A (es) |
| PL (1) | PL374731A1 (es) |
| RS (1) | RS20050008A (es) |
| RU (1) | RU2330858C2 (es) |
| WO (1) | WO2004005310A2 (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1483277A4 (en) * | 2002-02-15 | 2007-10-03 | Merckle Gmbh | CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS, METHODS OF PREPARATION AND USE, AND FORMULATION AND PHARMACEUTICAL APPLICATIONS |
| US7091196B2 (en) | 2002-09-26 | 2006-08-15 | Rib-X Pharmaceuticals, Inc. | Bifunctional heterocyclic compounds and methods of making and using same |
| WO2004078770A1 (en) * | 2003-03-05 | 2004-09-16 | Rib-X Pharmaceuticals, Inc. | Bifunctional heterocyclic compounds and methods of making and using the same |
| HRP20030324A2 (en) | 2003-04-24 | 2005-02-28 | Pliva-Istra�iva�ki institut d.o.o. | Compounds of antiinflammatory effect |
| JP2007509980A (ja) * | 2003-10-30 | 2007-04-19 | リブ−エックス ファーマシューティカルズ，インコーポレイテッド | 二官能性マクロライド複素環式化合物およびそれらの化合物を調製および使用する方法 |
| US20070270357A1 (en) * | 2003-11-18 | 2007-11-22 | Farmer Jay J | Bifunctional Macrolide Heterocyclic Compounds and Methods of Making and Using the Same |
| WO2005085266A2 (en) | 2004-02-27 | 2005-09-15 | Rib-X Pharmaceuticals, Inc. | Macrocyclic compounds and methods of making and using the same |
| US20060183696A1 (en) * | 2004-08-12 | 2006-08-17 | Pliva-Istrazivacki Institut D.O.O. | Use of immune cell specific conjugates for treatment of inflammatory diseases of gastrointestinal tract |
| RU2007108544A (ru) * | 2004-08-12 | 2008-09-20 | Глаксосмитклайн Истраживацки Центар Загреб Д.О.О.(Hr) | Применение клеточно-специфических конъюгатов для лечения воспалительных заболеваний желудочно-кишечного тракта |
| CN101090908A (zh) | 2004-10-27 | 2007-12-19 | 葛兰素伊斯特拉齐瓦基森塔萨格勒布公司 | 具有抗炎活性的共轭物 |
| ATE476438T1 (de) | 2005-01-13 | 2010-08-15 | Glaxosmithkline Zagreb | Makrolide mit entzündungshemmender wirkung |
| JP2008526945A (ja) * | 2005-01-14 | 2008-07-24 | グラクソスミスクライン・イストラジヴァッキ・センタル・ザグレブ・ドルズバ・ゼー・オメイェノ・オドゴヴォルノスティオ | 抗炎症活性を有する９ａ−カルバモイルおよびチオカルバモイルアザライド |
| JP2009502838A (ja) * | 2005-07-26 | 2009-01-29 | メルクレ，ゲーエムベーハー | ピロリジンおよびインドリジン化合物のマクロライド接合体 |
| JP2010528086A (ja) | 2007-05-29 | 2010-08-19 | ノバルティス アーゲー | 抗ｉｌ−１治療に関する新しい適応症 |
| WO2009006403A2 (en) * | 2007-06-29 | 2009-01-08 | Georgia Tech Research Corporation | Non-peptide macrocyclic histone deacetylase (hdac) inhibitors and methods of making and using thereof |
| US8871728B2 (en) | 2007-06-29 | 2014-10-28 | Georgia Tech Research Corporation | Non-peptide macrocyclic histone deacetylese (HDAC) inhibitors and methods of making and using thereof |
| WO2009055557A1 (en) | 2007-10-25 | 2009-04-30 | Cempra Pharmaceuticals, Inc. | Process for the preparation of macrolide antibacterial agents |
| HRP20160222T1 (hr) | 2008-10-24 | 2016-04-08 | Cempra Pharmaceuticals, Inc. | Biozaštite uporabom makrolida koji sadrže triazol |
| US20100160351A1 (en) * | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
| WO2010071865A1 (en) | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
| SG172782A1 (en) | 2009-01-30 | 2011-08-29 | Glaxo Group Ltd | Anti-inflammatory macrolide |
| US9937194B1 (en) * | 2009-06-12 | 2018-04-10 | Cempra Pharmaceuticals, Inc. | Compounds and methods for treating inflammatory diseases |
| AU2010292010B2 (en) | 2009-09-10 | 2016-01-07 | Cempra Pharmaceuticals, Inc. | Methods for treating malaria, tuberculosis and MAC diseases |
| WO2011032175A1 (en) | 2009-09-14 | 2011-03-17 | Nuon Therapeutics, Inc. | Combination formulations of tranilast and allopurinol and methods related thereto |
| JP6042334B2 (ja) | 2010-09-10 | 2016-12-14 | センプラ ファーマシューティカルズ，インコーポレイテッド | 疾患治療のための水素結合形成フルオロケトライド |
| HK1205939A1 (en) | 2012-03-27 | 2015-12-31 | Cempra Pharmaceuticals, Inc. | Parenteral formulations for administering macrolide antibiotics |
| US20140256032A1 (en) * | 2013-03-08 | 2014-09-11 | Church & Dwight Co., Inc. | Light scattering sperm assesment device and method |
| HK1217665A1 (zh) | 2013-03-14 | 2017-01-20 | 森普拉制药公司 | 用於治療呼吸道疾病的方法及其製劑 |
| AU2014233240B2 (en) | 2013-03-15 | 2018-08-09 | Cempra Pharmaceuticals, Inc. | Convergent processes for preparing macrolide antibacterial agents |
| CN103641869B (zh) * | 2013-12-30 | 2016-04-06 | 广州自远生物科技有限公司 | 一种泰拉菌素的合成方法 |
| ES2898508T3 (es) * | 2015-06-22 | 2022-03-07 | Brigham & Womens Hospital Inc | Evaluación domiciliaria de la calidad de muestras de semen |
| GB201520419D0 (en) | 2015-11-19 | 2016-01-06 | Epi Endo Pharmaceuticals Ehf | Compounds |
| GB201608236D0 (en) | 2016-05-11 | 2016-06-22 | Fidelta D O O | Seco macrolide compounds |
| CN111148750A (zh) * | 2017-04-20 | 2020-05-12 | 来兴泰德基金会 | 作为抗癌剂的包含鏻离子的阿奇霉素衍生物 |
| JP2020517748A (ja) * | 2017-04-20 | 2020-06-18 | ライジング タイド ファウンデーション | 抗がん剤としてホスホニウムイオンを含むアジスロマイシン誘導体 |
| GB202404587D0 (en) | 2024-03-28 | 2024-05-15 | Epiendo Pharmaceuticals Ehf | Chemical forms |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4710495A (en) * | 1980-07-10 | 1987-12-01 | Otsuka Pharmaceutical Co., Ltd. | Soft steroids having anti-inflammatory activity |
| US4474768A (en) * | 1982-07-19 | 1984-10-02 | Pfizer Inc. | N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor |
| ES2032831T5 (es) * | 1986-08-19 | 2001-02-16 | Genentech Inc | Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas. |
| DE3860503D1 (de) * | 1987-09-03 | 1990-10-04 | Pliva Pharm & Chem Works | 10-dihydro-10-deoxo-11-azaerythronolid-a-verbindungen,verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung in arzneimitteln und in deren herstellung. |
| LU87036A1 (fr) * | 1987-11-04 | 1989-06-14 | Oreal | Esters cycloaliphatiques insatures d'antibiotiques macrolidiques et lincosamidiques,leur procede de preparation et compositions pharmaceutiques et cosmetiques les contenant |
| SE9100342D0 (sv) | 1991-02-04 | 1991-02-04 | Astra Ab | Novel steroid esters |
| SE9100341D0 (sv) | 1991-02-04 | 1991-02-04 | Astra Ab | Novel steroids |
| GB9225923D0 (en) | 1992-12-11 | 1993-02-03 | Rhone Poulenc Rorer Ltd | New compositions of matter |
| FI953130A0 (fi) | 1992-12-24 | 1995-06-22 | Rhone Poulenc Rorer Ltd | Uudet steroidit |
| US5965566A (en) * | 1993-10-20 | 1999-10-12 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| FR2719587B1 (fr) | 1994-05-03 | 1996-07-12 | Roussel Uclaf | Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments. |
| CN1159756A (zh) | 1994-08-12 | 1997-09-17 | 大正制药株式会社 | 抑制白细胞介素5的产生的抑制剂 |
| KR970704455A (ko) | 1994-08-12 | 1997-09-06 | 우에하라 아끼라 | 인터류킨 5 생성 억제제(Interleukin 5 Production Inhibitor) |
| FR2742757B1 (fr) * | 1995-12-22 | 1998-01-30 | Roussel Uclaf | Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments |
| DE19616573C2 (de) * | 1996-04-25 | 1999-03-04 | Pari Gmbh | Verwendung unterkritischer Treibmittelmischungen und Aerosole für die Mikronisierung von Arzneimitteln mit Hilfe dichter Gase |
| US5928868A (en) * | 1996-04-26 | 1999-07-27 | Massachusetts Institute Of Technology | Three hybrid screening assay |
| GB2321455A (en) * | 1997-01-24 | 1998-07-29 | Norsk Hydro As | Lipophilic derivatives of biologically active compounds |
| HN1998000074A (es) | 1997-06-11 | 1999-01-08 | Pfizer Prod Inc | Derivados de macrolidos c-4 sustituidos |
| GB2327084A (en) | 1997-07-08 | 1999-01-13 | Merck & Co Inc | 9a-Aza-3-ketolide antibiotics |
| EP0895999A1 (en) | 1997-08-06 | 1999-02-10 | Pfizer Products Inc. | C-4" substituted macrolide antibiotics |
| JP3530004B2 (ja) * | 1998-02-06 | 2004-05-24 | 株式会社日立ユニシアオートモティブ | 吸入式投薬器 |
| HRP980189B1 (en) | 1998-04-06 | 2004-04-30 | Pliva Pharm & Chem Works | Novel 15-membered lactams ketolides |
| AU4549999A (en) * | 1998-06-08 | 1999-12-30 | Advanced Medicine, Inc. | Novel polyene macrolide compounds and uses |
| US6043227A (en) | 1998-08-19 | 2000-03-28 | Pfizer Inc. | C11 carbamates of macrolide antibacterials |
| CA2348741C (en) * | 1998-10-30 | 2010-04-20 | Nitromed Inc. | Nitrosasted and nitrosylated nonsteroidal antiinflammatory compounds, comositions and methods of use |
| IT1306205B1 (it) | 1999-01-15 | 2001-05-30 | Zambon Spa | Macrolidi ad attivita' antiinfiammatoria. |
| GB9909229D0 (en) * | 1999-04-23 | 1999-06-16 | Glaxo Group Ltd | Enantiomers of mercapto lactones and processes for their synthesis |
| HRP20010018A2 (en) * | 2001-01-09 | 2002-12-31 | Pliva D D | Novel anti-inflammatory compounds |
| US20040186063A1 (en) * | 2002-02-15 | 2004-09-23 | Hans-Jurgen Gutke | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
| NZ535355A (en) * | 2002-02-15 | 2007-09-28 | Merckle Gmbh | Antibiotic conjugates |
| WO2003070173A2 (en) | 2002-02-15 | 2003-08-28 | Sympore Gmbh | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
| EP1483277A4 (en) * | 2002-02-15 | 2007-10-03 | Merckle Gmbh | CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS, METHODS OF PREPARATION AND USE, AND FORMULATION AND PHARMACEUTICAL APPLICATIONS |
-
2003
- 2003-07-08 BR BR0312634-0A patent/BR0312634A/pt not_active IP Right Cessation
- 2003-07-08 RU RU2005103226/04A patent/RU2330858C2/ru not_active IP Right Cessation
- 2003-07-08 CN CN03816093A patent/CN100577681C/zh not_active Expired - Fee Related
- 2003-07-08 AU AU2003255851A patent/AU2003255851B2/en not_active Ceased
- 2003-07-08 PL PL03374731A patent/PL374731A1/xx unknown
- 2003-07-08 CA CA002489402A patent/CA2489402A1/en not_active Abandoned
- 2003-07-08 US US10/615,716 patent/US7091187B2/en not_active Expired - Fee Related
- 2003-07-08 NZ NZ537717A patent/NZ537717A/en not_active IP Right Cessation
- 2003-07-08 WO PCT/HR2003/000037 patent/WO2004005310A2/en not_active Ceased
- 2003-07-08 EP EP03762825A patent/EP1521764A2/en not_active Withdrawn
- 2003-07-08 RS YUP-2005/0008A patent/RS20050008A/sr unknown
- 2003-07-08 JP JP2004519021A patent/JP4790263B2/ja not_active Expired - Fee Related
- 2003-07-10 AR AR20030102488A patent/AR040484A1/es unknown
-
2005
- 2005-02-02 NO NO20050570A patent/NO329885B1/no not_active IP Right Cessation
- 2005-02-03 IS IS7684A patent/IS7684A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1082256A1 (zh) | 2006-06-02 |
| NO329885B1 (no) | 2011-01-17 |
| WO2004005310A2 (en) | 2004-01-15 |
| JP4790263B2 (ja) | 2011-10-12 |
| WO2004005310A3 (en) | 2004-04-22 |
| PL374731A1 (en) | 2005-10-31 |
| CN1692123A (zh) | 2005-11-02 |
| CA2489402A1 (en) | 2004-01-15 |
| IS7684A (is) | 2005-02-03 |
| NO20050570L (no) | 2005-03-04 |
| RU2330858C2 (ru) | 2008-08-10 |
| BR0312634A (pt) | 2005-05-10 |
| US7091187B2 (en) | 2006-08-15 |
| JP2005535654A (ja) | 2005-11-24 |
| RS20050008A (sr) | 2007-06-04 |
| EP1521764A2 (en) | 2005-04-13 |
| NZ537717A (en) | 2006-04-28 |
| US20040014685A1 (en) | 2004-01-22 |
| AU2003255851B2 (en) | 2009-07-23 |
| RU2005103226A (ru) | 2005-11-20 |
| AU2003255851A1 (en) | 2004-01-23 |
| CN100577681C (zh) | 2010-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR040484A1 (es) | Un compuesto, un proceso para la preparacion de dicho compuesto, y una composicion farmaceutica que comprende dicho compuesto | |
| AU618995B2 (en) | Pharmaceutical formulations for parenteral use | |
| BRPI0417341A (pt) | fator ix glicopeguilado | |
| BRPI0614839A2 (pt) | fator vii e fator viia glicopeguilados | |
| US9933419B2 (en) | Specific targeting of RNA expanded repeat sequences | |
| AR043103A1 (es) | Un compuesto antiinflamatorio y antiviral esteroide o no esteroide, un proceso para la preparacion del compuesto y una composicion farmaceutica que lo contiene | |
| RU2012145278A (ru) | Трансдермальное введение пептидов | |
| AR042145A1 (es) | Produccion de inmunoglobulinas en plantas con una fucocilacion reducida | |
| EP3381445A3 (en) | Aqueous formulation of antibody stablised by antioxidants for parenteral administration | |
| CO2024005877A2 (es) | Conjugados que comprenden fósforo (v) y una fracción molecular de droga | |
| BRPI0714844B8 (pt) | molécula de ácido nucleico e seus usos, composição farmaceutica e complexo | |
| Zapata‐Morales et al. | Antinociceptive activity of an ethanol extract of Justicia spicigera | |
| CN106589049B (zh) | 一种改进的雷公藤甲素-适配子偶合物的合成方法 | |
| WO2007044062A8 (en) | Bile preparations for gastrointestinal disorders | |
| FR2872165B1 (fr) | Nouveaux derives de pyrimido-benzimidazole | |
| AU2022208654B2 (en) | Compound or salt thereof, and antibody produced using same | |
| Choy et al. | Simple, unambiguous syntheses of 2, 3, 6-and 2, 4, 6-tri-O-methyl-d-mannose. | |
| DE602006017724D1 (de) | Salicylsäurederivate | |
| Leurs et al. | Design, synthesis, in vitro stability and cytostatic effect of multifunctional anticancer drug‐bioconjugates containing GnRH‐III as a targeting moiety | |
| Bini et al. | Bifunctional dendrons for multiple carbohydrate presentation via carbonyl chemistry | |
| Park et al. | Palmitoylation of octreotide for incorporation into poly (amidoamine) dendrimers | |
| WO1996024349B1 (es) | Composiciones farmaceuticas a base de aminometilindoles para su aplicacion terapeutica como neuroprotectores en las enfermedades de parkinson y alzheimer | |
| Kamga et al. | Politamide, a new constituent from the stem bark of Ficus polita Vahl (Moraceae) | |
| Solo et al. | Ring D bridged steroid analogs. 11. High Clauberg activity of 19-nor-14. alpha., 17. alpha.-ethano-4-pregnene-3, 20-dione | |
| TW200814995A (en) | Novel polygalatenosides and use thereof as an antidepressant agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |